NCT04696146View on ClinicalTrials.gov

Berinert (C1INH) vs Placebo for DGF/IRI

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

October 31, 2024

Conditions
End Stage Renal DiseaseChronic Kidney Diseases
Interventions
DRUG

Berinert

Intrarenal dose of 500 U of Berinert

DRUG

Placebo

Normal Saline placebo

Trial Locations (1)

90048

Cedars Sinai Medical Center, Los Angeles

All Listed Sponsors
collaborator

OneLegacy Foundation

UNKNOWN

lead

Cedars-Sinai Medical Center

OTHER

NCT04696146 - Berinert (C1INH) vs Placebo for DGF/IRI | Biotech Hunter | Biotech Hunter